体外診断薬市場：製品タイプ、検査タイプ、検体、用途、エンドユーザー別-2025-2030年世界予測

体外診断薬市場は、2024年には799億9,000万米ドルとなり、2025年には851億6,000万米ドル、CAGR6.79%で成長し、2030年には1,186億8,000万米ドルに達すると予測されています。

体外診断薬市場は、急速な技術革新、技術の進歩、正確でタイムリーな診断ソリューションに対する世界の需要の高まりにより、かつてないペースで進化しています。今日の検査プロトコールと技術的ブレークスルーは、臨床上の意思決定を強化するだけでなく、業界の競合の枠組みを再構築しつつあります。本レポートでは、まず市場の現状と将来の可能性に焦点を当て、まとまりのある詳細なイントロダクションを提供します。本レポートでは、精密機器、先進試薬、包括的なサービスツール、堅牢なソフトウェアソリューションの統合が、世界の診断プロセスの質をいかに高めているかに焦点を当てています。さらに、個別化医療、分子生物学、デジタル統合の最近の動向も綿密に検証し、強力な文脈的基盤を提供しています。規制当局の監視が強化され、品質とアクセシビリティが世界的に求められる中、科学的発見と技術革新のダイナミックな相互作用が本分析の中核を成しています。意思決定者や業界専門家向けに専門的なトーンと明確な洞察により、このイントロダクションで抽出された全体的なフレームワークは、市場の進化する戦略と変革的要素への深堀りのための舞台となります。

In-Vitro Diagnosticsの変貌を探る

市場は、競合情勢や投資家心理を大きく変化させる変革的なシフトを目の当たりにしてきました。急速な技術導入が診断薬におけるデジタルトランスフォーメーションの波に拍車をかけ、企業はデジタルインターフェース、自動化、データ分析を取り入れて業務を合理化するようになりました。こうしたシフトは、複雑な健康状態を迅速かつ正確に検出するために、これまで以上に洗練された機器と統合されたソフトウェア・ソリューションが中心となり、診断精度の概念を再定義しています。これと並行して、規制改革や高品質な医療検査への要求の高まりにより、企業は精度と効率性の両方を具現化する先進的なプラットフォームへの投資を進めています。世界なデジタル化、テクノロジー・プロバイダーとヘルスケア機関のパートナーシップ、患者中心のアウトカム重視の再定義が融合し、イノベーションのための肥沃な環境が整いつつあります。さらに、進化する消費者の期待とデジタルヘルスの動向は、研究開発への多額の投資を促し、レガシーシステムを次世代技術へと急速にアップグレードすることを後押ししています。高度なアナリティクス、自動化、積極的な規制状況の強力な組み合わせは、市場力学を再構築し続け、従来の境界を平らにし、リアルタイムでテクノロジーとヘルスケアの洞察を融合させるパラダイムを促進しています。

市場力学を牽引する主なセグメンテーション洞察

市場セグメンテーションの詳細な洞察により、体外診断薬市場を詳細に理解し、多様で戦略的に重要なサブカテゴリーを明らかにします。製品タイプに基づく詳細な評価では、市場は機器、試薬・キット、サービス、ソフトウェアに区分され、機器はさらに分析装置、自動化システム、シーケンス機器に区分されます。試薬とキットは、酵素や染色などのユニークな領域を包含し、サービスの構成要素は、キャリブレーションサービス、コンサルタントサービス、メンテナンスサービスなどの重要な運用機能をカバーしています。さらに、ソフトウェアに基づくセグメンテーションでは、データ管理ソフトウェアと診断ソフトウェアを対比し、テクノロジーの中心的役割を強調しています。市場を検査タイプ別に見ると、臨床化学、血液学、免疫測定、微生物学、分子診断学を通じて、利用可能な診断薬の幅広さが浮かび上がります。例えば、臨床化学は、血液分析、電解質パネル、肝臓パネル、甲状腺機能パネル、尿分析などの観点から検討されます。一方、免疫アッセイのような検査タイプは、化学発光、比色法、酵素結合免疫吸着アッセイ、酵素結合免疫スポットアッセイ、蛍光、放射免疫アッセイなどの技術を組み込んでいます。さらに、分子診断学分野では、DNAシーケンシング、次世代シーケンシング、等温核酸増幅技術、ポリメラーゼ連鎖反応に注目します。さらに、血液、血清・血漿、唾液、組織検体、尿などの検体別セグメンテーションが詳細な分析を補完しています。用途別調査では、自己免疫疾患のモニタリング、がんの検出、心疾患のモニタリング、糖尿病の管理、遺伝子検査、感染症のスクリーニングに重点が置かれていることが明らかになり、エンドユーザー別では、学術・研究センター、診断研究所、病院、ポイントオブケア検査センターに及んでいます。これらのセグメンテーションパラメーターは、市場の複雑さと、各ニッチに効果的に対処するための個別戦略の必要性を強調しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 早期発見と継続的なモニタリングを必要とする慢性疾患の蔓延
    • 個別化治療への関心の高まりとコンパニオン診断の導入増加
    • ヘルスケアアクセスの改善を目的とした政府の取り組みと支援的な規制政策の拡大
  • 抑制要因
    • 特定の診断検査に対する包括的な償還ポリシーの欠如
  • 機会
    • 迅速かつ信頼性の高い診断結果を提供するポイントオブケア検査技術の進歩
    • 診断機器にデジタルヘルスソリューションとデータ分析を統合し、精度を向上
  • 課題
    • 体外診断に関連する厳格な規制と承認プロセス
• 市場セグメンテーション分析
  • 検体：がんの早期発見に血液、血清、血漿の利用が増加
  • アプリケーション：世界中で糖尿病の罹患率が上昇し、体外診断ソリューションの需要が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 体外診断薬市場：製品タイプ別

• 機器
  • アナライザー
  • 自動化システム
  • シーケンシング機器
• 試薬とキット
  • 酵素
  • 汚れ
• サービス
  • 校正サービス
  • コンサルティングサービス
  • メンテナンスサービス
• ソフトウェア
  • データ管理ソフトウェア
  • 診断ソフトウェア

第7章 体外診断薬市場テストの種類別

• 臨床化学
  • 血液検査
  • 電解質パネル
  • 肝臓パネル
  • 甲状腺機能パネル
  • 尿検査
• 血液学
• 免疫測定
  • 化学発光免疫測定
  • 比色免疫測定
  • 酵素免疫測定法
  • 酵素結合免疫スポットアッセイ
  • 蛍光免疫測定
  • ラジオイムノアッセイ
• 微生物学
• 分子診断
  • DNAシーケンシングと次世代シーケンシング
  • 等温核酸増幅技術
  • ポリメラーゼ連鎖反応

第8章 体外診断薬市場標本別

• 血液、血清、血漿
• 唾液
• 組織サンプル
• 尿

第9章 体外診断薬市場：用途別

• 自己免疫疾患
• がん検出
• 心臓モニタリング
• 糖尿病管理
• 遺伝子検査
• 感染症検査

第10章 体外診断薬市場：エンドユーザー別

• 学術研究センター
• 診断検査室
• 病院
• ポイントオブケア検査センター

第11章 南北アメリカの体外診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の体外診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの体外診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 10x Genomics, Inc.
• Abbott Laboratories
• Adaptive Biotechnologies Corp
• Agilent Technologies Inc.
• Arkray Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Biomerieux SA
• Danaher Corporation
• DiaSorin S.p.A.
• EKF GmbH
• F. Hoffmann-La Roche Ltd.
• Grifols SA
• Hologic, Inc.
• Illumina, Inc.
• Menarini Diagnostics
• Mindray Medical International Limited
• Myriad Genetics, Inc.
• Ortho-Clinical Diagnostics, Inc.
• Qiagen GmbH
• Randox Laboratories
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. IN-VITRO DIAGNOSTICS MARKET MULTI-CURRENCY
• FIGURE 2. IN-VITRO DIAGNOSTICS MARKET MULTI-LANGUAGE
• FIGURE 3. IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 4. IN-VITRO DIAGNOSTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IN-VITRO DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 81. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 93. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 94. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 95. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 96. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 99. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 100. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 101. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 105. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 106. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 108. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 110. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 111. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 112. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 113. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 117. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 118. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 119. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 120. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 122. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 123. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 124. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 125. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 129. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 130. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 131. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 132. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 134. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 135. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 136. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 137. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 140. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 142. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 144. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 146. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 148. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 150. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 153. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 155. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 156. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 157. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 158. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 159. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 160. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 161. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 162. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 163. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 167. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 168. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 169. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 170. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 171. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 172. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 173. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 174. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 175. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 179. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 180. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 181. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 182. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 183. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 184. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 185. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 186. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 187. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 191. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 192. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 193. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 194. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 195. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 196. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 197. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 198. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 199. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 203. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 204. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 205. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 206. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 207. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 208. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 209. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 210. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 211. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 215. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 216. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 217. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 218. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 219. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 220. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 221. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 222. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 223. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 227. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 228. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 229. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 230. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 231. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 232. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 233. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 234. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 235. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 239. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 240. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 241. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 242. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 244. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 245. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 246. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 247. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 258. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 261. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 263. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 264. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 265. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 266. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 268. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 269. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 270. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 271. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 273. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 274. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 275. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 276. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 277. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 278. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 279. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 280. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 281. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 282. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 283. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 285. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 286. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 287. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 288. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 289. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 290. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 291. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 292. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 293. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 294. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 295. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 296. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 310. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 311. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 312. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 313. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 314. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 315. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 316. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 317. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 318. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 319. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 320. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 321. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 322. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 323. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 324. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 325. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 326. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 327. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 328. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
• TABLE 329. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 330. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 331. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 332. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 333. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 334. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 335. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 336. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 337. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 338. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 339. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2

The In-Vitro Diagnostics Market was valued at USD 79.99 billion in 2024 and is projected to grow to USD 85.16 billion in 2025, with a CAGR of 6.79%, reaching USD 118.68 billion by 2030.

The in-vitro diagnostics market is evolving at an unprecedented pace, driven by rapid innovations, technological advances, and a growing global demand for accurate and timely diagnostic solutions. Today's testing protocols and technological breakthroughs not only enhance clinical decision making but are also reshaping the industry's competitive framework. This report opens by offering a cohesive and detailed introduction to the market, highlighting both its current standing and future potential. The narrative focuses on how the integration of precision instruments, advanced reagents, comprehensive service tools, and robust software solutions is bolstering the quality of diagnostic processes worldwide. Furthermore, recent trends in personalized medicine, molecular biology, and digital integration are meticulously examined, providing a strong contextual foundation. Amid rising regulatory oversight and the global push towards quality and accessibility, the dynamic interplay between scientific discovery and technological innovation forms the core of this analysis. With a professional tone and clear insights tailored for decision-makers and industry experts, the overall framework distilled in this introduction sets the stage for a deep dive into the market's evolving strategies and transformative elements.

Exploring Transformative Shifts in the In-Vitro Diagnostics Landscape

The market has witnessed transformative shifts that have significantly altered the competitive landscape and investor sentiment. Rapid technological adoption has spurred a wave of digital transformation in diagnostics, pushing companies to incorporate digital interfaces, automation, and data analytics to streamline operations. These shifts have redefined the concept of diagnostic accuracy as ever-more sophisticated instruments and integrated software solutions become central to detecting complex health conditions swiftly and accurately. In parallel, regulatory reforms and increasing demands for high-quality medical testing drive companies to invest in advanced platforms that embody both precision and efficiency. Global digitalization, partnerships between technology providers and healthcare organizations, and a redefined emphasis on patient-centric outcomes have converged to create a fertile environment for innovation. Furthermore, evolving consumer expectations and digital health trends have inspired substantial investments in research and development, pushing legacy systems to rapidly upgrade into next-generation technologies. This potent combination of advanced analytics, automation, and a proactive regulatory landscape continues to reshape market dynamics, flattening traditional boundaries and promoting a paradigm that fuses technology with healthcare insight in real time.

Key Segmentation Insights Driving Market Dynamics

Deep segmentation insights offer a granular understanding of the in-vitro diagnostics market, revealing diverse and strategically important sub-categories. A detailed evaluation based on product type shows that the market is segmented into instruments, reagents and kits, services, and software, with instruments further divided into analyzers, automation systems, and sequencing instruments. Reagents and kits encapsulate unique domains such as enzymes and stains, while the services component covers critical operational functions such as calibration services, consultancy services, and maintenance services. Additionally, the segmentation based on software contrasts data management software with diagnostic software, underlining technology's central role. When the market is studied by test type, the breadth of available diagnostics emerges through clinical chemistry, hematology, immunoassays, microbiology, and molecular diagnostics. For instance, clinical chemistry is examined in the context of blood analysis, electrolyte panels, liver panels, thyroid function panels, and urine analysis, whereas testing types like immunoassays incorporate techniques including chemiluminescence, colorimetric methods, enzyme-linked immunosorbent assays, enzyme-linked immunospot assays, fluorescence, and radioimmunoassays. Additionally, the molecular diagnostics segment is dissected to highlight DNA sequencing together with next-generation sequencing, isothermal nucleic acid amplification technology, and polymerase chain reaction. Further segmentation by specimen-covering blood, serum and plasma, saliva, tissue samples, and urine-complements the detailed analysis. Insights into application reveal emphasis on monitoring autoimmune diseases, detecting cancer, cardia monitoring, managing diabetes, genetic testing, and screening for infectious diseases, while the end user dimension spans academic and research centers, diagnostic laboratories, hospitals, and point-of-care testing centers. Together these segmentation parameters underscore the market's complexity and the need for tailored strategies to address each niche effectively.

Based on Product Type, market is studied across Instruments, Reagents & Kits, Services, and Software. The Instruments is further studied across Analyzers, Automation Systems, and Sequencing Instrument. The Reagents & Kits is further studied across Enzymes and Stains. The Services is further studied across Calibration Services, Consultancy Services, and Maintenance Services. The Software is further studied across Data Management Software and Diagnostic Software.

Based on Test Type, market is studied across Clinical Chemistry, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics. The Clinical Chemistry is further studied across Blood Analysis, Electrolyte Panel, Liver Panel, Thyroid Function Panel, and Urine Analysis. The Immunoassays is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assays, Fluorescence Immunoassays, and Radioimmunoassay. The Molecular Diagnostics is further studied across DNA Sequencing & Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology, and Polymerase Chain Reaction.

Based on Specimen, market is studied across Blood, Serum & Plasma, Saliva, Tissue Samples, and Urine.

Based on Application, market is studied across Autoimmune Diseases, Cancer Detection, Cardiac Monitoring, Diabetes Management, Genetic Testing, and Infectious Disease Testing.

Based on End User, market is studied across Academic & Research Centers, Diagnostic Laboratories, Hospitals, and Point-Of-Care Testing Centers.

Regional Trends Influencing Global Diagnostics Markets

Regional dynamics continue to shape the in-vitro diagnostics industry profoundly, with various parts of the world contributing uniquely to market trends. Market drivers in the Americas reflect a mature yet innovative framework that combines robust healthcare infrastructure with a forward-thinking approach to adopting new technologies, underscoring its position as a leader in early diagnostic innovation. Meanwhile, insights from Europe, Middle East and Africa illustrate a balanced confluence of regulatory authority, investment in research, and rising public health initiatives that are steadily broadening diagnostic capabilities across diverse demographic groups. The Asia-Pacific region demonstrates remarkable growth potential fueled by rapid industrialization, increased healthcare spending, and an expanding pool of patients seeking high-quality diagnostic solutions. Economic development, urbanization, and government-driven healthcare initiatives in this region further accelerate technological adoption and innovation. The interplay of these regional trends not only diversifies the competitive landscape but also presents unique opportunities and challenges that vary by geography. Thus, understanding the regional distinctions in infrastructure, regulatory requirements, and consumer behavior is pivotal to developing a strategic market approach that leverages local insights while aligning with global market trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Leaders Enhancing Innovation and Driving Progress

The industry's competitive landscape is largely defined by a roster of influential companies that continue to drive innovation and push boundaries within the in-vitro diagnostics space. Leaders such as 10x Genomics, Inc. and Abbott Laboratories have set benchmarks in technological advancements and market penetration. Adaptive Biotechnologies Corp and Agilent Technologies Inc. are noted for their substantial contributions to next-generation diagnostic platforms. Other prominent players include Arkray Inc. and Becton, Dickinson and Company, both of which have continuously reinforced their reputations through robust research and development. Bio-Rad Laboratories Inc. and Biomerieux SA exemplify excellence in product quality and service reliability. Moreover, industry giants like Danaher Corporation, DiaSorin S.p.A., and EKF GmbH have significantly expanded innovative offerings through strategic investments and mergers. F. Hoffmann-La Roche Ltd. and Grifols SA have capitalized on emerging trends, while Hologic, Inc. and Illumina, Inc. have consistently invested in advanced sequencing technologies. Companies such as Menarini Diagnostics and Mindray Medical International Limited further highlight market dynamism through their expansive product portfolios, and trailblazers like Myriad Genetics, Inc. and Ortho-Clinical Diagnostics, Inc. have set industry standards in specialized testing. Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc. are also making substantial inroads by driving research innovations and service enhancements. The collective influence of these key corporate players not only spurs significant market advancement but also shapes the emerging paradigms and standards for tomorrow's diagnostics.

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc.. Actionable Strategies for Maintaining Industry Leadership

For industry leaders, a forward-looking strategy is paramount to harnessing the rapid transformation in the in-vitro diagnostics market. Companies should prioritize investment in digital technologies and automation to streamline operations and boost diagnostic accuracy. Embracing emerging trends such as artificial intelligence, machine learning, and big data analytics can further enhance testing protocols and result interpretations. It is vital to continuously innovate product portfolios by focusing on tailored solutions across diverse segmentation categories including instruments, reagents and kits, services, and diagnostic software. Additionally, an integrated approach that combines investment in research and development with strategic partnerships is necessary to overcome market challenges and capture new opportunities. Leaders must ensure regulatory compliance while concurrently championing innovations that meet the evolving expectations of both clinical practitioners and end users. Consideration of regional dynamics is also critical; adapting strategies to cater to the unique needs of mature markets in the Americas, the balanced sectors in Europe, Middle East and Africa, and the rapidly growing regions in Asia-Pacific will provide a competitive advantage. Diversification of offerings, coupled with robust market intelligence driven by detailed segmentation, enables firms to navigate uncertainties while setting the pace for the future of diagnostic excellence.

Synthesizing Insights and Concluding Market Perspectives

In conclusion, the in-vitro diagnostics market is characterized by dynamic shifts that have fundamentally altered its competitive landscape and operational frameworks. The detailed analysis presented here underscores how technological innovation, regulatory evolution, and regional realignments contribute to the current market momentum. The segmentation insights reveal a vast spectrum of products and services that require tailored strategies to meet the nuanced needs of various diagnostic pathways and end user profiles. As companies continue to invest in next-generation platforms and harness the power of digital transformation, the interplay between technological precision and operational efficiency emerges as a central theme. The synthesis of regional trends offers critical insights into localized market behaviors, while the comprehensive review of industry leaders highlights the competitive forces driving innovation. Ultimately, strategic foresight combined with agile execution will be the cornerstone of future success in this increasingly competitive environment, ensuring that the industry remains not only reactive to change but also proactive in shaping the trajectory of diagnostic advancements.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases that necessitate early detection and consistent monitoring
    • 5.1.1.2. Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
    • 5.1.1.3. Expanding government initiatives and supportive regulatory policies aimed at improving healthcare access
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of comprehensive reimbursement policies for certain diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in point-of-care testing technologies that offer rapid and reliable diagnostic results
    • 5.1.3.2. Integration of digital health solutions and data analytics in diagnostic equipment for enhanced accuracy
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and approval processes associated with in vitro diagnostics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Specimen: Growing use of blood and, serum & plasma for early cancer detection
  • 5.2.2. Application: Rising prevalence of diabetes across the globe boosts demand for in vitro diagnostics solutions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In-Vitro Diagnostics Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
  • 6.2.1. Analyzers
  • 6.2.2. Automation Systems
  • 6.2.3. Sequencing Instrument
• 6.3. Reagents & Kits
  • 6.3.1. Enzymes
  • 6.3.2. Stains
• 6.4. Services
  • 6.4.1. Calibration Services
  • 6.4.2. Consultancy Services
  • 6.4.3. Maintenance Services
• 6.5. Software
  • 6.5.1. Data Management Software
  • 6.5.2. Diagnostic Software

7. In-Vitro Diagnostics Market, by Test Type

• 7.1. Introduction
• 7.2. Clinical Chemistry
  • 7.2.1. Blood Analysis
  • 7.2.2. Electrolyte Panel
  • 7.2.3. Liver Panel
  • 7.2.4. Thyroid Function Panel
  • 7.2.5. Urine Analysis
• 7.3. Hematology
• 7.4. Immunoassays
  • 7.4.1. Chemiluminescence Immunoassays
  • 7.4.2. Colorimetric Immunoassays
  • 7.4.3. Enzyme-Linked Immunosorbent Assay
  • 7.4.4. Enzyme-Linked Immunospot Assays
  • 7.4.5. Fluorescence Immunoassays
  • 7.4.6. Radioimmunoassay
• 7.5. Microbiology
• 7.6. Molecular Diagnostics
  • 7.6.1. DNA Sequencing & Next-Generation Sequencing
  • 7.6.2. Isothermal Nucleic Acid Amplification Technology
  • 7.6.3. Polymerase Chain Reaction

8. In-Vitro Diagnostics Market, by Specimen

• 8.1. Introduction
• 8.2. Blood, Serum & Plasma
• 8.3. Saliva
• 8.4. Tissue Samples
• 8.5. Urine

9. In-Vitro Diagnostics Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Diseases
• 9.3. Cancer Detection
• 9.4. Cardiac Monitoring
• 9.5. Diabetes Management
• 9.6. Genetic Testing
• 9.7. Infectious Disease Testing

10. In-Vitro Diagnostics Market, by End User

• 10.1. Introduction
• 10.2. Academic & Research Centers
• 10.3. Diagnostic Laboratories
• 10.4. Hospitals
• 10.5. Point-Of-Care Testing Centers

11. Americas In-Vitro Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific In-Vitro Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa In-Vitro Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. CeRAI at IIT Madras and Roche join forces to integrate advanced analytics and ethical AI for transformative patient-centric in-vitro diagnostics and sustainable digital health innovation
  • 14.3.2. Akoya Biosciences and Argonaut Manufacturing expand their strategic collaboration to scale high-quality IVD companion diagnostics for precision medicine initiatives
  • 14.3.3. Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry
  • 14.3.4. GenWorks Health launches IVD tests for dengue & malaria
  • 14.3.5. Oxford Nanopore and bioMerieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 10x Genomics, Inc.
• 2. Abbott Laboratories
• 3. Adaptive Biotechnologies Corp
• 4. Agilent Technologies Inc.
• 5. Arkray Inc.
• 6. Becton, Dickinson and Company
• 7. Bio-Rad Laboratories Inc.
• 8. Biomerieux SA
• 9. Danaher Corporation
• 10. DiaSorin S.p.A.
• 11. EKF GmbH
• 12. F. Hoffmann-La Roche Ltd.
• 13. Grifols SA
• 14. Hologic, Inc.
• 15. Illumina, Inc.
• 16. Menarini Diagnostics
• 17. Mindray Medical International Limited
• 18. Myriad Genetics, Inc.
• 19. Ortho-Clinical Diagnostics, Inc.
• 20. Qiagen GmbH
• 21. Randox Laboratories
• 22. Siemens AG
• 23. Sysmex Corporation
• 24. Thermo Fisher Scientific, Inc.